Contributions of gender and systemic estradiol and testosterone concentrations to maximal secretagogue drive of burst-like growth hormone secretion in healthy middle-aged and older adults.

Veldhuis JD, Patrie JT, Brill KT, Weltman JY, Mueller EE, Bowers CY, Weltman A

The Journal of clinical endocrinology and metabolism1 Dec 2004Cited by 17 (Europe PMC)

PMID15579792DOI10.1210/jc.2004-0644PepBankPUB-15579792

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged and older adults, GH secretion after GHRP‑2 injection was greater in men than in women.
In plain wordsIn healthy older adults, a GHRP‑2 injection raised growth hormone release more in men than in women.
Peptide
GHRP-2
Outcome
IncreaseGH secretion after GHRP-2 in men versus women
Study
n = 16
Comparator
Women
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Gender comparisons disclosed greater GH secretion in men than women after somatostatin-induced rebound (P = 0.008) and GHRP-2 injection (P < 0.001) and conversely greater GH secretion in women than men after saline (P = 0.013).
1 context sentence(design, population, supporting numbers)
Summary · context
To test whether concentrations of estradiol and testosterone predict GH responses to mechanistically distinct secretagogues in healthy older adults, we studied 16 volunteers (n = 10 men, n = 6 women, age 49-72 yr) in each of six randomly ordered sessions as follows: 1) saline; 2) l-arginine; 3) aero…
Report a problemFND-1557979203
02HumanRandomized controlled trialMechanism
In healthy middle-aged and older adults, individual estradiol and testosterone concentrations and their combination strongly predicted GH responses to GHRP‑2 only.
In plain wordsIn healthy older adults, a person's estradiol and testosterone levels were linked to their growth hormone response to GHRP‑2, but not to the other tests.
Peptide
GHRP-2
Outcome
Not applicablePrediction of GHRP-2 response by estradiol and testosterone
Study
n = 16
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Correlation with GHRP-2 response, estradiol
0.8 r
Correlation with GHRP-2 response, testosterone
0.63 r
Correlation with GHRP-2 response, combination
0.86 r
Source sentences
Summary
Regression analysis showed that individual concentrations of estradiol (r = 0.80, P = 0.002) and testosterone (r = 0.63, P = 0.008) and their combination (r = 0.86, P < 0.001) strongly predict responses to GHRP-2 only.
1 context sentence(design, population, supporting numbers)
Summary · context
To test whether concentrations of estradiol and testosterone predict GH responses to mechanistically distinct secretagogues in healthy older adults, we studied 16 volunteers (n = 10 men, n = 6 women, age 49-72 yr) in each of six randomly ordered sessions as follows: 1) saline; 2) l-arginine; 3) aero…
Report a problemFND-1557979204

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

03HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy middle-aged and older women, most secretagogues stimulated GH secretion 2.6- to 6.4-fold over saline or rest, except exercise and somatostatin-induced rebound.
In plain wordsIn healthy older women, most growth hormone stimulation tests raised growth hormone release compared with saline or rest. Exercise and somatostatin rebound did not.
Peptide
GHRP-2
Outcome
IncreaseGH secretion after secretagogues in women
Study
n = 16
Comparator
Saline or rest
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In women, each secretagogue, except exercise and somatostatin-induced rebound, stimulated GH secretion by 2.6- to 6.4-fold over saline/rest (P < 0.023).
1 context sentence(design, population, supporting numbers)
Summary · context
To test whether concentrations of estradiol and testosterone predict GH responses to mechanistically distinct secretagogues in healthy older adults, we studied 16 volunteers (n = 10 men, n = 6 women, age 49-72 yr) in each of six randomly ordered sessions as follows: 1) saline; 2) l-arginine; 3) aero…
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1557979201
04HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy middle-aged and older men, somatostatin-induced rebound, exercise and other secretagogues stimulated GH secretion 4.6- to 109-fold over saline or rest.
In plain wordsIn healthy older men, all growth hormone stimulation tests raised growth hormone release compared with saline or rest.
Peptide
GHRP-2
Outcome
IncreaseGH secretion after secretagogues in men
Study
n = 16
Comparator
Saline or rest
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In men, somatostatin-induced rebound drove GH secretion by 4.6-fold (P = 0.004), exercise by 16-fold (P < 0.001), and other secretagogues by 18- to 109-fold over saline/rest (each P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
To test whether concentrations of estradiol and testosterone predict GH responses to mechanistically distinct secretagogues in healthy older adults, we studied 16 volunteers (n = 10 men, n = 6 women, age 49-72 yr) in each of six randomly ordered sessions as follows: 1) saline; 2) l-arginine; 3) aero…
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1557979202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.